NL-OMON46824
Completed
Not Applicable
The clinical evaluation of the effectiveness of two oral probiotic strains on gingival health. - The PrOH-ACT study
Academisch Centrum Tandheelkunde Amsterdam (ACTA)0 sites117 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- mondgezondheid
- Sponsor
- Academisch Centrum Tandheelkunde Amsterdam (ACTA)
- Enrollment
- 117
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Willing and able to give written informed consent and willing and able to comply to all study procedures; Adult, \* 18 years \- 55 years; Systemically healthy, as assessed by a medical questionnaire (no systemic diseases); Minimum of 20 natural teeth: at least the first or second molar must be present in each quadrant; Having visited the dentist for a regular check\-up within the last year and having finished the necessary treatment(s);
Exclusion Criteria
- •ACTA dental student or ACTA employee; Participation in a clinical study within the previous 30 days; Allergy/Intolerance to the test and placebo products (ingredients) in particular lactose and milk protein content (allergens) in the test products; not having a good general health and/or oral health.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
De beoordeling van de effectiviteit van twee probiotica bij het in stand houden van de mondgezondheid: een praktijkonderzoek.NL-OMON25529Ir. W. Th. FokkemaACTA Dental Research B.V. (ADR)Gustav Mahlerlaan 30041081 LA Amsterdam, NLw.fokkema@acta.nl / +31 6 28 724 788117
Completed
Not Applicable
A Clinical Study to evaluate the effect of two different combinations of BP medication in patients with uncontrolled BPCTRI/2018/08/015555Current Medical Concepts Pvt Ltd93
Recruiting
Phase 3
Comparison of the clinical effectiveness of the two different doses of Meropenem in pneumoniaIRCT20100107003014N19Sari University of Medical Sciences62
Active, not recruiting
Phase 1
A clincial study comparing the effectiveness of two doses of the drug Rituximab during long-term treatment of the neurological disease Multiple Sclerosis.EUCTR2018-000721-31-SEDepartment of Clinical Sciences, Karolinska Institutet Danderyd Hospital200
Active, not recruiting
Phase 1
A clincial study comparing the effectiveness of two drugs, named Rituximab and Dimethyl Fumarate (Tecfidera®), for the neurological disease Multiple Sclerosis.Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 years of disease duration (from diagnosis). Patients treated with immunomodulatory drugs or treated with first-line injectable therapies (eg interferons or glatiramer acetate) may be included.Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2015-004116-38-SEDepartment of Clinical Sciences, Danderyd Hospital200